CastleKnight Management LP Reduces Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CastleKnight Management LP lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 23.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 167,400 shares of the company's stock after selling 51,500 shares during the period. CastleKnight Management LP's holdings in Teva Pharmaceutical Industries were worth $3,689,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $58,243,000. Marshall Wace LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock worth $113,625,000 after purchasing an additional 2,410,420 shares during the period. Finally, Northern Trust Corp boosted its position in Teva Pharmaceutical Industries by 69.0% in the fourth quarter. Northern Trust Corp now owns 5,206,360 shares of the company's stock valued at $114,748,000 after buying an additional 2,125,266 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded down $1.13 on Friday, hitting $16.94. The company's stock had a trading volume of 19,072,081 shares, compared to its average volume of 10,043,801. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a fifty day moving average price of $15.18 and a 200-day moving average price of $17.46. The company has a market capitalization of $19.21 billion, a price-to-earnings ratio of -11.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.48 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the subject of several research reports. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Barclays decreased their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $23.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.